Compare AbbVie Inc (ABBV) vs Acadia Healthcare Company Inc (ACHC) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.

The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.